Table E1.
MRI Feature-based PFS Analysis for Entire Follow-Up Period
| Imaging feature | Number | Log-rank | Weighted log-rank | Median PFS (95% CI) | ||
|---|---|---|---|---|---|---|
| Chi-square | P value | Chi-square | P value | |||
| Multifocality | 10.387 | .006 | 7.862 | .020 | ||
| 1 tumor | 49 (75.4%) | 22.0 (22.6–32.8) | ||||
| 2 tumors | 12 (18.5%) | 15.0 (12.2–24.4) | ||||
| 3 tumors | 4 (6.2%) | 10.5 (0.2–20.8) | ||||
| Observation size | 0.019 | .89 | 0.003 | .96 | ||
| <2 cm | 28 (43.1%) | 24.0 (20.4–32.8) | ||||
| ≥2 cm | 37 (56.9%) | 18.0 (17.9–29.4) | ||||
| APHE | 1.273 | .26 | 0.620 | .43 | ||
| Absent | 6 (9.2%) | 27.0 (7.9–39.1) | ||||
| Present | 59 (90.8%) | 19.0 (20.7–29.5) | ||||
| Heterogeneity of APHE | 1.457 | .48 | 1.798 | .41 | ||
| Absent | 6 (9.2%) | 27.0 (7.9–39.1) | ||||
| Homogeneous | 30 (46.2%) | 21.5 (18.5–32.2) | ||||
| Heterogeneous | 29 (44.6%) | 18.0 (18.8–30.7) | ||||
| Nonperipheral “washout” | 0.027 | .87 | 0.037 | .85 | ||
| Absent | 15 (23.1%) | 22.0 (16.0–34.7) | ||||
| Present | 50 (76.9%) | 19.0 (20.0–29.6) | ||||
| Enhancing “capsule” | 1.883 | .17 | 2.684 | .10 | ||
| Absent | 19 (29.2%) | 31.0 (22.7–39.9) | ||||
| Present | 46 (70.8%) | 16.5 (17.7–26.9) | ||||
| Continuity of enhancing “capsule” | 2.123 | .35 | 6.325 | .042 | ||
| Absent | 19 (29.2%) | 31.0 (22.7–39.9) | ||||
| Discontinuous | 31 (47.7%) | 17.0 (17.8–27.5) | ||||
| Continuous | 15 (23.1%) | 13.0 (10.4–32.7) | ||||
APHE = arterial phase hyperenhancement; CI = confidence interval; PFS = progression-free survival.